FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Seymour

Research Profile

Procedures

Concepts & Ideas

Chemicals & Drugs

Disorders

Co-author Network

Publications

TOP 3
Harry Iland; John F Seymour
Role of arsenic trioxide in acute promyelocytic leukemia.
Eric Wong; Kirsten Herbert; Melita Kenealy; John F Seymour; David Westerman; Michael Dickinson
Treatment of chronic myelomonocytic leukemia with azacitidine.
Amit Khot; H Miles Prince; John F Seymour; Kerrie Stokes; Dominic Wall; Kate Burbury; Michael Dickinson; Shaun Fleming; Peter Gambell; Simon Harrison; David Ritchie
A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantation.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Seymour (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Harry Iland; John F Seymour
Role of arsenic trioxide in acute promyelocytic leukemia.
Current treatment options in oncology 2013;14(2):170-84.
2013: Eric Wong; Kirsten Herbert; Melita Kenealy; John F Seymour; David Westerman; Michael Dickinson
Treatment of chronic myelomonocytic leukemia with azacitidine.
Leukemia & lymphoma 2013;54(4):878-80.
2013: Amit Khot; H Miles Prince; John F Seymour; Kerrie Stokes; Dominic Wall; Kate Burbury; Michael Dickinson; Shaun Fleming; Peter Gambell; Simon Harrison; David Ritchie
A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantation.
Clinical lymphoma, myeloma & leukemia 2013;13(1):42-7.
2013: Kate L Burbury; Ray Dauer; John F Seymour; David Westerman
Under-recognition of platelet dysfunction in myelodysplastic syndromes: are we only seeing the tip of the iceberg?
Leukemia & lymphoma 2013;54(1):11-3.
2012: Harry Iland; John Moore; John Reynolds; Michael Seldon; John F Seymour; Shane G Supple; Jeff Szer; John Taper; Kerry Taylor; Campbell Tiley; John Bashford; Kenneth F Bradstock; Peter Browett; Alberto Catalano; Marnie Collins; Juliana Di Iulio; Robin Filshie; Frank Firkin; Andrew Grigg; Mark Hertzberg; Amanda Hugman
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Blood 2012;120(8):1570-80; quiz 1752.
2012: Shaun Fleming; Kate Burbury; Eva Hellström-Lindberg; John F Seymour
Paraneoplastic large vessel arteritis complicating myelodysplastic syndrome.
Leukemia & lymphoma 2012;53(8):1613-6.
2012: C Y Cheah; H Januszewicz; S M Lim; J Scarlett; D A Carney; John F Seymour
Local experience with the novel human anti-CD20 antibody, ofatumumab, as salvage treatment for patients with heavily pretreated chronic lymphocytic leukaemia.
Internal medicine journal 2012;42(7):846-8.
2012: R Ralli; John F Seymour; A P Wiegmans; K M Banks; D Carney; R W Johnstone; A E Alsop
Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro.
Leukemia 2012;26(6):1433-5.
2012: John F Seymour
Osteolytic bone lesions in non-transformed chronic lymphocytic leukemia are not as rare as suggested.
Leukemia & lymphoma 2012;53(5):1011; author reply 1012.
2012: Andrew W Roberts; John F Seymour; William G Wierda; Hao Xiong; Seong Lin Khaw; Thomas J Kipps; Andrew Krivoshik; Evelyn M McKeegan; Jennifer R Brown; Todd A Busman; Dennis A Carney; Yue Cui; Sari H Enschede; Simon Z He; David C S Huang; Rod A Humerickhouse
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(5):488-96.
2011: Senthil Lingaratnam; Linda Mileshkin; Mary O'Reilly; H Miles Prince; John F Seymour; Monica A Slavin; Jeff Szer; Craig A Bennett; Andrew Dalton; Sue W Kirsa; Bogda Koczwara; Leon J Worth; Karin Thursky
A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment.
Australian health review : a publication of the Australian Hospital Association 2011;35(4):491-500.
2011: David M Ross; John F Seymour; Paul A Bartley; Jarrad Goyne; Alexander A Morley; Andrew P Grigg
Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features.
Haematologica 2011;96(11):1720-2.
2011: Shane A Gangatharan; Melita K Kenealy; H Miles Prince; Lynda J Campbell; Dennis A Carney; John F Seymour
Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.
European journal of haematology 2011;87(2):186-8.
2011: Kirsten E Herbert; David S Ritchie; John F Seymour
Strategies to optimize collection of hematopoietic stem cells in patients with mantle cell lymphoma receiving hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate (Hyper-CVAD) chemotherapy.
Leukemia & lymphoma 2011;52(6):935-7.
2011: P A Thompson; H Miles Prince; John F Seymour; D Ritchie; K Stokes; K Burbury; Max Wolf; Stefan Peinert; T Joyce; S J Harrison
Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma.
Bone marrow transplantation 2011;46(5):764-5.
2011: Kate Burbury; Lee Ping Chew; David Westerman; Alberto Catalano; John F Seymour
Concomitant FIP1L1-PDGFRA fusion gene and T-cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib.
Leukemia & lymphoma 2011;52(2):335-8.
2011: S Lingaratnam; Monica A Slavin; Linda Mileshkin; Benjamin Solomon; K Burbury; John F Seymour; R Sharma; B Koczwara; S W Kirsa; I D Davis; M Prince; Jeff Szer; C Underhill; O Morrissey; Karin Thursky
An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009.
Internal medicine journal 2011;41(1b):110-20.
2011: S Lingaratnam; Monica A Slavin; B Koczwara; John F Seymour; Jeff Szer; C Underhill; M Prince; Linda Mileshkin; M O'Reilly; S W Kirsa; C A Bennett; I D Davis; O Morrissey; Karin Thursky
Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Australian Consensus Guidelines 2011 Steering Committee.
Internal medicine journal 2011;41(1b):75-81.
2010: D A Carney; David Westerman; Constantine S Tam; A Milner; H Miles Prince; M Kenealy; Max Wolf; E Henry Januszewicz; David Ritchie; N Came; John F Seymour
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.
Leukemia 2010;24(12):2056-62.
2010: Stefan Peinert; Constantine S Tam; H Miles Prince; John Scarlett; Max M Wolf; E Henry Januszewicz; David Westerman; John F Seymour
Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia.
Leukemia & lymphoma 2010;51(12):2188-97.
2010: John F Seymour; Pierre Fenaux; Lewis R Silverman; Ghulam J Mufti; Eva Hellström-Lindberg; Valeria Santini; Alan F List; Steven D Gore; Jay Backstrom; David McKenzie; C L Beach
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.
Critical reviews in oncology/hematology 2010;76(3):218-27.
2010: Dennis A Carney; John F Seymour
Therapy-related myelodysplasia and fludarabine combination therapy - do the benefits justify the risk?
Leukemia & lymphoma 2010;51(11):1957-9.
2010: Stefan Peinert; John F Seymour
Unresolved issues in the comparison of therapies and determination of responses in Waldenström macroglobulinemia.
Leukemia & lymphoma 2010;51(10):1767-70.
2010: Adrian R Tramontana; Biju George; Aeron C Hurt; Joseph S Doyle; Katherine Langan; Alistair B Reid; Janet M Harper; Karin Thursky; Leon J Worth; Dominic E Dwyer; C Orla Morrissey; Paul Johnson; Kirsty L Buising; Simon James Harrison; John F Seymour; Patricia E Ferguson; Bin Wang; Justin Denholm; Allen C Cheng; Monica Slavin
Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia.
Emerging infectious diseases 2010;16(7):1068-75.
2010: Michael Dickinson; Rosemary Hoyt; Andrew W Roberts; Andrew Grigg; John F Seymour; H Miles Prince; Jeff Szer; David Ritchie
Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy.
British journal of haematology 2010;150(1):39-45.
2010: Mark J Bishton; John F Seymour
What is responsible for the recent improvements in outlook for patients with follicular lymphoma?
Leukemia & lymphoma 2010;51(6):960-2.
2010: S Gill; D Carney; David Ritchie; Max Wolf; David Westerman; H Miles Prince; H Januszewicz; John F Seymour
The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(2):331-4.
2010: Kirsten E Herbert; H Miles Prince; David S Ritchie; John F Seymour
The role of ancestim (recombinant human stem-cell factor, rhSCF) in hematopoietic stem cell mobilization and hematopoietic reconstitution.
Expert opinion on biological therapy 2010;10(1):113-25.
2009: Saar Gill; Kirsten E Herbert; H Miles Prince; Max M Wolf; Andrew Wirth; Gail Ryan; Dennis A Carney; David S Ritchie; John M Davies; John F Seymour
Mantle cell lymphoma with central nervous system involvement: frequency and clinical features.
British journal of haematology 2009;147(1):83-8.
2009: Stefan Peinert; Dennis Carney; H Miles Prince; E Henry Januszewicz; John F Seymour
Fludarabine combinations for patients with advanced marginal zone lymphomas--best treatment option or too toxic?
British journal of haematology 2009;146(6):685-6.
2009: Leon J Worth; John F Seymour; Monica A Slavin
Infective and thrombotic complications of central venous catheters in patients with hematological malignancy: prospective evaluation of nontunneled devices.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009;17(7):811-8.
2009: Walid Rasheed; Brendan Flaim; John F Seymour
Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.
Leukemia research 2009;33(6):861-4.
2009: M Dickinson; H Miles Prince; S Kirsa; A Zannettino; Simon Gibbs; Linda Mileshkin; J O'Grady; John F Seymour; J Szer; N Horvath; D E Joshua
Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment.
Internal medicine journal 2009;39(5):304-16.
2009: Stefan Peinert; Sarah Kamel; John F Seymour; H Miles Prince
Intralesional rituximab for the treatment of localised palatal relapse of follicular lymphoma.
Leukemia & lymphoma 2009;50(2):303-5.
2009: Hang Quach; Linda Mileshkin; John F Seymour; Alvin Milner; David Ritchie; Simon Harrison; David Westerman; H Miles Prince
Predicting durable remissions following thalidomide therapy for relapsed myeloma.
Leukemia & lymphoma 2009;50(2):223-9.
2009: K E Herbert; S Morgan; H Miles Prince; David Westerman; Max M Wolf; D A Carney; K Yuen; Juliana Di Iulio; John F Seymour
Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator.
Leukemia 2009;23(2):305-12.
2008: Timothy P Hughes; Susan Branford; Deborah L White; John Reynolds; Rachel Koelmeyer; John F Seymour; Kerry Taylor; Chris Arthur; Anthony P Schwarer; James Morton; Julian Cooney; Michael F Leahy; Philip Rowlings; John Catalano; Mark Hertzberg; Robin Filshie; Anthony K Mills; Keith Fay; Simon Durrant; Henry Januszewicz; David Joske; Craig Underhill; Scott Dunkley; Kevin Lynch; Andrew Grigg
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.
Blood 2008;112(10):3965-73.
2008: Stefan Peinert; John F Seymour
Indolent lymphomas other than follicular and marginal zone lymphomas.
Hematology/oncology clinics of North America 2008;22(5):903-40, viii.
2008: Saar Gill; Rodney J Hicks; John F Seymour
What is the role of 18F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?
Leukemia & lymphoma 2008;49(9):1653-6.
2008: M J Bishton; M F Leahy; R J Hicks; J H Turner; A D McQuillan; John F Seymour
Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(9):1629-33.
2008: Saar Gill; Steven W Lane; Julie Crawford; Gavin Cull; David Joske; Paula Marlton; Peter N Mollee; H Miles Prince; John F Seymour
Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients.
Annals of hematology 2008;87(9):727-34.
2008: Saar Gill; Max Wolf; H Miles Prince; H Januszewicz; David Ritchie; Rodney J Hicks; John F Seymour
[18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma.
Clinical lymphoma & myeloma 2008;8(3):159-65.
2008: Karin Thursky; E G Playford; John F Seymour; T C Sorrell; D H Ellis; S D Guy; N Gilroy; J Chu; D R Shaw
Recommendations for the treatment of established fungal infections.
Internal medicine journal 2008;38(6b):496-520.
2008: Leon J Worth; James Black; John F Seymour; Karin Thursky; Monica A Slavin
Surveillance for catheter-associated bloodstream infection in hematology units: quantifying the characteristics of a practical case definition.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2008;29(4):358-60.
2008: G Ryan; G Martinelli; M Kuper-Hommel; R Tsang; Giancarlo Pruneri; Kally Yuen; D Roos; A Lennard; liliana devizzi; S Crabb; D Hossfeld; G Pratt; M Dell'Olio; S P Choo; R G Bociek; J Radford; S Lade; ALESSANDRO MASSIMO GIANNI; Emanuele Zucca; Franco Cavalli; John F Seymour
Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(2):233-41.
2007: Susan Branford; John F Seymour; Andrew Grigg; Chris Arthur; Zbigniew Rudzki; Kevin Lynch; Timothy Hughes
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(23):7080-5.
2007: Leon J Worth; Karin Thursky; John F Seymour; Monica A Slavin
Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk.
European journal of haematology 2007;79(3):226-33.
2007: Margaret L Hibbs; Cathy Quilici; Nicole Kountouri; John F Seymour; Jane E Armes; Antony W Burgess; Ashley R Dunn
Mice lacking three myeloid colony-stimulating factors (G-CSF, GM-CSF, and M-CSF) still produce macrophages and granulocytes and mount an inflammatory response in a sterile model of peritonitis.
Journal of immunology (Baltimore, Md. : 1950) 2007;178(10):6435-43.
2007: David S Ritchie; John F Seymour; Andrew P Grigg; Andrew W Roberts; R Hoyt; S Thompson; Jeff Szer; H Miles Prince
The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
Annals of hematology 2007;86(2):101-5.
2006: Constantine S Tam; John F Seymour; H Miles Prince; Melita Kenealy; Max Wolf; E Henry Januszewicz; David Westerman
Treatment-related myelodysplasia following fludarabine combination chemotherapy.
Haematologica 2006;91(11):1546-50.
2006: Linda Mileshkin; Richard Stark; Bruce Day; John F Seymour; Jerome B Zeldis; H Miles Prince
Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(27):4507-14.
2006: Mark Polizzotto; Constantine S Tam; Alvin Milner; E Henry Januszewicz; H Miles Prince; David Westerman; Max M Wolf; John F Seymour
The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders.
Cancer 2006;107(4):773-80.
2006: Constantine S Tam; Max Wolf; H Miles Prince; E Henry Januszewicz; David Westerman; Katherine I Lin; Dennis Carney; John F Seymour
Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Cancer 2006;106(11):2412-20.
2006: Janine Campbell; John F Seymour; Jane Matthews; Max Wolf; Janey Stone; Surender Juneja
The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement.
European journal of haematology 2006;76(6):473-80.
2006: Mark Polizzotto; Simon Gibbs; W Beswick; John F Seymour
Cardiac involvement in Henoch-Schönlein purpura.
Internal medicine journal 2006;36(5):328-31.
2006: Karin Thursky; Leon J Worth; John F Seymour; H Miles Prince; Monica A Slavin
Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.
British journal of haematology 2006;132(1):3-12.
2005: Ashley Ng; Leon Worth; Luke F. Chen; John F Seymour; H Miles Prince; Monica Slavin; Karin Thursky
Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.
Haematologica 2005;90(12):1672-9.
2005: Simon Gibbs; John O'Grady; John F Seymour; H Miles Prince
Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention.
The Medical journal of Australia 2005;183(10):549-50.
2005: Linda Mileshkin; John F Seymour; Max M Wolf; P Gates; E Henry Januszewicz; P Joyce; H Miles Prince
Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older.
Leukemia & lymphoma 2005;46(11):1575-9.
2005: Constantine S Tam; Max M Wolf; David Westerman; E Henry Januszewicz; H Miles Prince; John F Seymour
Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
Clinical lymphoma & myeloma 2005;6(2):136-9.
2005: Simon Gibbs; David Westerman; Stephen Lade; Christopher McCormack; John F Seymour; H Miles Prince
Early B-cell chronic lymphocytic leukemia presenting as cutaneous lesions with a normal peripheral blood lymphocyte count.
Journal of the American Academy of Dermatology 2005;53(3):535-6.
2005: H Miles Prince; Linda Mileshkin; Andrew Roberts; Vinod Ganju; Craig Underhill; John Catalano; Richard Bell; John F Seymour; David Westerman; Paul J Simmons; Kate Lillie; Alvin D Milner; Juliana Di Iulio; Jerome B Zeldis; Robert Ramsay
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(15):5504-14.
2005: shriram nath; John F Seymour
Cure of a patient with profoundly chemotherapy-refractory primary mediastinal large B-cell lymphoma: role of rituximab, high-dose therapy, and allogeneic stem cell transplantation.
Leukemia & lymphoma 2005;46(7):1075-9.
2005: H Miles Prince; Geoff Regester; Priscilla Gates; Lina Jablonskis; John F Seymour; Kate Lillie; Raelene West; Max Wolf; Henry Januszewicz; David Belford
A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2005;11(7):512-20.
2005: Simon Gibbs; David Westerman; Christopher McCormack; John F Seymour; H Miles Prince
Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders.
British journal of haematology 2005;130(1):87-91.
2005: Dirk Hönemann; H Miles Prince; John F Seymour; Max M Wolf; David Westerman; E Henry Januszewicz
A phase II study of liposomal doxorubicin, vincristine and dexamethasone in multiple myeloma.
Leukemia & lymphoma 2005;46(6):945-7.
2005: S Brennand; V R Sutton; J Biagi; J A Trapani; David Westerman; Christopher McCormack; John F Seymour; G Kennedy; H Miles Prince
Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy.
The British journal of dermatology 2005;152(6):1199-205.
2005: Fiona Chionh; Kirsten E Herbert; John F Seymour; H Miles Prince; Max Wolf; Alan Zimet; Constantine Tam; Glen A Kennedy
Ante-mortem diagnosis of localized invasive esophageal aspergillosis in a patient with acute myeloid leukemia.
Leukemia & lymphoma 2005;46(4):603-5.
2005: L J Worth; M J Dooley; John F Seymour; L Mileshkin; M A Slavin; Karin Thursky
An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital.
British journal of cancer 2005;92(5):867-72.
2005: J J Biagi; K E Herbert; C Smith; E Abdi; M Leahy; C Falkson; Max Wolf; H Januszewicz; John F Seymour; K Richards; Jane P Matthews; B Dale; H Miles Prince
A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma.
Leukemia & lymphoma 2005;46(2):197-206.
2004: PN Mollee; C Arthur; T Hughes; H Januszewicz; Andrew Grigg; Kenneth F Bradstock; Max Wolf; J Gibson; Anthony P Schwarer; A Spencer; Peter Browett; T Hawkins; M Seldon; R Herrmann; A Watson; John F Seymour; N Martin; S Shina; C Low; S Wright; Robyn Rodwell; J Coulston; J Morton; H Blacklock; D Taylor; K M Taylor
Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(12):1810-5.
2004: Simon Gibbs; Kirsten E Herbert; Christopher McCormack; John F Seymour; H Miles Prince
Alemtuzumab: effective monotherapy for simultaneous B-cell chronic lymphocytic leukaemia and Sézary syndrome.
European journal of haematology 2004;73(6):447-9.
2004: Constantine S Tam; Max M Wolf; E Henry Januszewicz; Andrew P Grigg; H Miles Prince; David Westerman; John F Seymour
A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies.
Cancer 2004;101(9):2042-9.
2004: Susan Branford; Zbigniew Rudzki; Ian Parkinson; Andrew Grigg; Kerry Taylor; John F Seymour; Simon Durrant; Peter Browett; Anthony P Schwarer; Chris Arthur; John Catalano; Michael F Leahy; Robin Filshie; Kenneth F Bradstock; Richard Herrmann; David Joske; Kevin Lynch; Timothy Hughes
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.
Blood 2004;104(9):2926-32.
2004: Jeffrey J Presneill; Koh Nakata; Yoshikazu Inoue; John F Seymour
Pulmonary alveolar proteinosis.
Clinics in chest medicine 2004;25(3):593-613, viii.
2004: Constantine S Tam; J Galanos; John F Seymour; A G Pitman; R J Stark; H Miles Prince
Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies.
American journal of hematology 2004;77(1):72-6.
2004: H Miles Prince; Paul J Simmons; Genevieve A Whitty; Dominic P Wall; Lesley Barber; Guy C Toner; John F Seymour; Gary Richardson; Robert Mrongovius; David N Haylock
Improved haematopoietic recovery following transplantation with ex vivo-expanded mobilized blood cells.
British journal of haematology 2004;126(4):536-45.
2004: Susan J Morgan; John F Seymour; H Miles Prince; David Westerman; Max M Wolf
Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3572-5.
2004: Constantine S Tam; Max M Wolf; E Henry Januszewicz; H Miles Prince; David Westerman; John F Seymour
Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
Cancer 2004;100(10):2181-9.
2004: S J Morgan; John F Seymour; Andrew Grigg; Jane P Matthews; H Miles Prince; Max M Wolf; E Henry Januszewicz
Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine.
Leukemia 2004;18(5):1034-8.
2004: Constantine S Tam; H Miles Prince; David Westerman; John F Seymour; Surender Juneja
Leukaemic subtype of marginal zone lymphoma: a presentation of three cases and literature review.
Leukemia & lymphoma 2004;45(4):705-10.
2004: Monica Slavin; Jeff Szer; Andrew P Grigg; Andrew W Roberts; John F Seymour; J Sasadeusz; Karin Thursky; S C Chen; Catherine Morrissey; C H Heath; T Sorrell
Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections.
Internal medicine journal 2004;34(4):192-200.
2004: John F Seymour
New treatment approaches to indolent non-Hodgkin's lymphoma.
Seminars in oncology 2004;31(1 Suppl 2):27-32.
2004: John F Seymour; Jeffrey J Presneill
Pulmonary alveolar proteinosis. What is the role of GM-CSF in disease pathogenesis and treatment?
Treatments in respiratory medicine 2004;3(4):229-34.
2004: Linda Mileshkin; Robert Blum; John F Seymour; Andrew Patrikeos; Rodney J Hicks; H Miles Prince
A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma.
European journal of haematology 2004;72(1):32-7.
2003: Susan Branford; Zbigniew Rudzki; A Harper; Andrew Grigg; Kerry Taylor; Simon Durrant; Chris Arthur; Peter Browett; Anthony P Schwarer; D Ma; John F Seymour; Kenneth F Bradstock; David Joske; Kevin Lynch; Insa Gathmann; Timothy P Hughes
Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Leukemia 2003;17(12):2401-9.
2003: Linda Mileshkin; H Miles Prince; John F Seymour; James J Biagi
Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide.
British journal of haematology 2003;123(4):747-8; author reply 748.
2003: H Miles Prince; Christopher McCormack; Gail Ryan; Rod O'Keefe; John F Seymour; Chris Baker
Management of the primary cutaneous lymphomas.
The Australasian journal of dermatology 2003;44(4):227-40; quiz 241-2.
2003: Christina Ng; Monica A Slavin; John F Seymour
Progressive multifocal leukoencephalopathy complicating Waldenström's macroglobulinaemia.
Leukemia & lymphoma 2003;44(10):1819-21.
2003: G A Kennedy; John F Seymour; M Wolf; H Januszewicz; J Davison; Christopher McCormack; Gail Ryan; H Miles Prince
Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab.
European journal of haematology 2003;71(4):250-6.
2003: J N Machatschek; David Westerman; H Miles Prince; John F Seymour
A case of clinical indolent natural killer cell lineage large granular lymphocytic leukemia in a patient with rheumatoid arthritis.
Leukemia & lymphoma 2003;44(7):1223-7.
2003: Linda Mileshkin; James J Biagi; Paul Mitchell; Craig Underhill; Andrew Grigg; Richard Bell; Joe McKendrick; Peter Briggs; John F Seymour; Kate Lillie; Jennifer G Smith; Jerome B Zeldis; H Miles Prince
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.
Blood 2003;102(1):69-77.
2003: Susan Branford; Zbigniew Rudzki; Sonya Walsh; Ian Parkinson; Andrew Grigg; Jeff Szer; Kerry Taylor; Richard Herrmann; John F Seymour; Chris Arthur; David Joske; Kevin Lynch; Timothy Hughes
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
Blood 2003;102(1):276-83.
2003: John F Seymour; Barbara Pro; Lillian M Fuller; John T Manning; Fredrick B Hagemeister; Jorge Romaguera; Maria A Rodriguez; Chul Ha; Terry L Smith; Ana Ayala; Mark Hess; James D Cox; Fernando Cabanillas; Peter McLaughlin
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(11):2115-22.
2003: Lee Mei Yap; Robert Blum; Peter Foley; Christopher McCormack; Hugh Turner; John F Seymour; H Miles Prince
Clinical study of primary cutaneous B-cell lymphoma using both the European Organization for Research and Treatment of Cancer and World Health Organization classifications.
The Australasian journal of dermatology 2003;44(2):110-5.
2003: Chi-hung Hui; K Y Goh; D White; Susan Branford; Andrew Grigg; John F Seymour; Yiu Lam Kwan; Sonya Walsh; R Hoyt; Annette Trickett; B Rudzki; D D F Ma; L Bik To; Timothy P Hughes
Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR.
Leukemia 2003;17(5):821-8.
2003: JK Campbell; Jane P Matthews; John F Seymour; Max M Wolf; Surender Juneja
Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(2):273-6.
2002: Robert Blum; John F Seymour; Rodney J Hicks
Role of 18FDG-positron emission tomography scanning in the management of histiocytosis.
Leukemia & lymphoma 2002;43(11):2155-7.
2002: C Tam; H Turner; R J Hicks; John F Seymour
Diffuse large B-cell non-Hodgkin's lymphoma presenting as Sister Joseph's nodule.
Leukemia & lymphoma 2002;43(10):2055-7.
2002: S L Chua; John F Seymour; J Streater; Max M Wolf; E Henry Januszewicz; H Miles Prince
Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma.
Leukemia & lymphoma 2002;43(9):1783-8.
2002: John F Seymour; Jeffrey J Presneill
Pulmonary alveolar proteinosis: progress in the first 44 years.
American journal of respiratory and critical care medicine 2002;166(2):215-35.
2002: K Field; M A Slavin; John F Seymour
Severe respiratory syncytial virus pneumonia complicating fludarabine and cyclophosphamide treatment of chronic lymphocytic leukemia.
European journal of haematology 2002;69(1):54-7.
2002: James J Biagi; John F Seymour
Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation.
Blood 2002;99(12):4265-75.
2002: R Blum; John F Seymour; Guy C Toner
Significant impairment of high-dose methotrexate clearance following vancomycin administration in the absence of overt renal impairment.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(2):327-30.
2002: John F Seymour; Andrew P Grigg; Jeff Szer; Richard M Fox
Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
Cancer 2002;94(3):585-93.
2002: H Miles Prince; D Wall; Danny Rischin; Guy C Toner; John F Seymour; D Blakey; David N Haylock; P Simmons; Max Wolf; E Henry Januszewicz; David Westerman; Gary Richardson; J Scarlett; P Briggs
CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy.
Cytotherapy 2002;4(2):147-55.
2002: H Miles Prince; John Bashford; D Wall; Danny Rischin; N Parker; Guy C Toner; John F Seymour; D Blakey; David N Haylock; P Simmons; P Francis; Max Wolf; E Henry Januszewicz; Gary Richardson; J Scarlett; P Briggs
Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy.
Cytotherapy 2002;4(2):137-45.
2001: B Ma; John F Seymour; H Januszewicz; Monica A Slavin
Cure of pulmonary Rhizomucor pusillus infection in a patient with hairy-cell leukemia: role of liposomal amphotericin B and GM-CSF.
Leukemia & lymphoma 2001;42(6):1393-9.
2001: John F Seymour; Andrew P Grigg; Jeff Szer; Richard M Fox
Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(10):1455-60.
2001: Linda Mileshkin; Monica A Slavin; John F Seymour; A McKenzie
Successful treatment of rhinocerebral zygomycosis using liposomal nystatin.
Leukemia & lymphoma 2001;42(5):1119-23.
2001: J A Thomson; John F Seymour; Max Wolf
Hodgkin's disease complicated by the nephrotic syndrome in a man with Kugelberg-Welander disease.
Leukemia & lymphoma 2001;42(3):561-6.
2001: A J Dowling; H Miles Prince; A Wirth; M Wolf; E Henry Januszewicz; Surender Juneja; John F Seymour; P Gates; J G Smith
High-dose therapy and autologous transplantation for lymphoma: The Peter MacCallum Cancer Institute experience.
Internal medicine journal 2001;31(5):279-89.
2001: David S Ritchie; John F Seymour; Andrew W Roberts; Jeff Szer; Andrew P Grigg
Acute left ventricular failure following melphalan and fludarabine conditioning.
Bone marrow transplantation 2001;28(1):101-3.
2001: JK Campbell; H M Prince; Surender Juneja; John F Seymour; M Slavin
Diffuse large cell lymphoma and t(8;22) (q24;q11) in a patient with idiopathic CD4+ T-lymphopenia.
Leukemia & lymphoma 2001;41(3-4):421-3.
2000: H Miles Prince; Danny Rischin; Guy C Toner; John F Seymour; D Blakey; P Gates; S Eerhard; Peter Chapple; M Quinn; M Brettell; Surender Juneja; Max Wolf; E Henry Januszewicz; Gary Richardson; J Scarlett; P Briggs
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Bone marrow transplantation 2000;26(9):955-61.
2000: H Miles Prince; Guy C Toner; John F Seymour; D Blakey; P Gates; S Eerhard; Peter Chapple; D Wall; M Quinn; Surender Juneja; Max Wolf; E Henry Januszewicz; Gary Richardson; J Scarlett; P Briggs; M Brettell; Danny Rischin
Docetaxel effectively mobilizes peripheral blood CD34+ cells.
Bone marrow transplantation 2000;26(5):483-7.
2000: S L Chua; John F Seymour; H Miles Prince
Deafness from eighth cranial nerve involvement in a patient with large-cell transformation of mycosis fungoides.
European journal of haematology 2000;64(5):340-3.
2000: Surender Juneja; L Trute; David Westerman; Deon J Venter; John F Seymour; H Miles Prince
Paraffin section immunotyping of leukaemias.
British journal of haematology 2000;109(2):267-71.
1999: H Miles Prince; Michael J Millward; Danny Rischin; D Blakey; P Francis; P Gates; Peter Chapple; M Quinn; Surender Juneja; Max Wolf; E Henry Januszewicz; John F Seymour; M Brettell; A Strickland; John Zalcberg; Gary Richardson; J Scarlett; P Briggs; Guy C Toner
Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(4):479-81.
1997: John F Seymour; GJ Lieschke; Dianne Grail; Cathy Quilici; George Hodgson; Ashley R Dunn
Mice lacking both granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF have impaired reproductive capacity, perturbed neonatal granulopoiesis, lung disease, amyloidosis, and reduced long-term survival.
Blood 1997;90(8):3037-49.